News Center

News Center

Character | Chen Bin: A "Gatekeeper" at the "Stove" of Drug Analysis

Character | Chen Bin: A "Gatekeeper" at the "Stove" of Drug Analysis

In the process of "cooking" the drug, quality and safety control must be ensured by "gatekeepers" like drug analysts—only then can a high-quality, reliable medicine truly benefit patients.

Time：2022-09-23 15:37

Media Spotlight | Yu Qiang: The Entrepreneurial Journey of a "Veteran" in the Pharmaceutical Industry

Media Spotlight | Yu Qiang: The Entrepreneurial Journey of a "Veteran" in the Pharmaceutical Industry

Yu Qiang, founder and CEO of Shitaike Biopharmaceutical Technology (Suzhou) Co., Ltd., expressed his satisfaction, adding that after more than a decade of relentless effort, the company has finally taken its first monumental step in an ambitious journey.

Time：2022-09-23 15:26

Media Spotlight | Dr. Wang Tong: Embarking on the "Stellar Voyage" of Drug Discovery, Starting from a Fragment-Molecule Library

Media Spotlight | Dr. Wang Tong: Embarking on the "Stellar Voyage" of Drug Discovery, Starting from a Fragment-Molecule Library

Recently, Mingxin Talk featured an interview with Dr. Tong Wang, Chief Scientific Officer of Shengshi Taikang, who shared insights into the research and development strategies—and emerging trends—of precision-targeted small-molecule anticancer drugs.

Time：2022-09-23 15:19

Shengshi Taikang Named Most Promising Innovative Pharmaceutical Company

Shengshi Taikang Named Most Promising Innovative Pharmaceutical Company

Today, exciting news came from the 6th China Biopharmaceutical Innovation Collaboration Conference and the 2022 China Biopharmaceutical Industry Value List Awards Ceremony: Shengshi Taikang was named among the "Top 10 Most Promising Small-Molecule Innovative Drug Companies." Over the past month, Shengshi Taikang has seen two of its pipeline innovative drug candidates receive dual approvals—both in China and the U.S.—marking the start of a new chapter in the global expansion of its groundbreaking therapies.

Time：2022-08-16 12:31

China-U.S. Dual Filing Scores Another Victory: Shengshi Taikang's Next-Generation ALK Inhibitor Approved for Clinical Trials in the U.S.

China-U.S. Dual Filing Scores Another Victory: Shengshi Taikang's Next-Generation ALK Inhibitor Approved for Clinical Trials in the U.S.

Today, Shengshi Taikang’s independently developed next-generation ALK inhibitor, CGT-9475, has received approval from the U.S. Food and Drug Administration (FDA) to enter clinical trials. This breakthrough drug is expected to address several critical clinical challenges in lung cancer treatment, such as drug resistance and brain metastasis. This marks another milestone for Shengshi Taikang, following the recent dual U.S.-China approval of its CXCR4 antagonist CGT-1881 for clinical trials—highlighting the company’s growing presence and innovation in global drug development.

Time：2022-08-09 15:50

Dr. Yu Qiang: Striking a balance between stability and innovation to develop high-quality, differentiated products.

Dr. Yu Qiang: Striking a balance between stability and innovation to develop high-quality, differentiated products.

Recently, Shengshi Taikang announced back-to-back approvals for two innovative drug candidates currently in development, marking the start of their global clinical development journey—both applications were submitted simultaneously in China and the U.S. Earlier this January, Shengshi Taikang’s first product, teriflunomide—a treatment for multiple sclerosis—received regulatory approval, officially propelling the company into its commercialization phase. Meanwhile, the company’s new diabetes drug, a DPP-4 inhibitor called fosdegrelin phosphate, has already entered the final stages of its Phase 3 clinical trials.

Time：2022-08-09 15:47

China's first domestically produced teriflunomide tablet hits the market, bringing new hope for ensuring access to treatments for rare diseases.

China's first domestically produced teriflunomide tablet hits the market, bringing new hope for ensuring access to treatments for rare diseases.

Today, the first domestically produced teriflunomide tablet developed by Shengshi Tai has been launched for sale. The initial batch of patients will benefit in key cities such as Beijing, Shanghai, Guangzhou, Chengdu, and Suzhou, with nationwide coverage expected to follow soon, providing a new treatment option and ensuring reliable drug supply for multiple sclerosis patients across China.

Time：2022-08-09 15:27

Shengshi Taikang Completes First China-U.S. Dual-Reporting New Drug Project, Embarking on Its Overseas Journey

Shengshi Taikang Completes First China-U.S. Dual-Reporting New Drug Project, Embarking on Its Overseas Journey

Today, CGT-1881, a CXCR4 antagonist independently developed by Shengshi Taikang, has received approval from the U.S. Food and Drug Administration (FDA) to enter clinical trials. The drug is intended for mobilizing hematopoietic stem cells in patients with blood cancers. This milestone follows the product’s clinical trial approval from China’s National Medical Products Administration (NMPA) back in June of this year, marking Shengshi Taikang’s first-ever dual-regulatory submission—both in China and the U.S.—for a new drug project.

Time：2022-07-12 15:31

< 1...456...10 >
中企跨境-全域组件 制作前进入CSS配置样式

在线客服添加返回顶部

页面顺滑的滚动

屏蔽页面上图片的alt/title提示

右侧在线客服样式 1,2,3 2

图片alt标题设置： Fland Environmental

表单验证提示文本： The content cannot be empty!

循环体没有内容时： Content is being organized—please wait!

CSS / JS 文件放置地